Health Care [ 8/12 ] | Biotechnology [ 33/76 ]
NASDAQ | Common Stock
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.34 Decreased by -21.43% | -0.28 Decreased by -21.43% |
| May 14, 24 | -0.25 Increased by +10.71% | -0.26 Increased by +3.85% |
| Mar 26, 24 | -0.28 Increased by +12.50% | -0.26 Decreased by -7.69% |
| Nov 13, 23 | -0.24 Increased by +7.69% | -0.27 Increased by +11.11% |
| Aug 8, 23 | -0.28 Decreased by -12.00% | -0.35 Increased by +20.00% |
| May 9, 23 | -0.28 Decreased by -21.74% | -0.35 Increased by +20.00% |
| Mar 27, 23 | -0.32 Increased by +23.81% | -0.25 Decreased by -28.00% |
| Nov 14, 22 | -0.26 Decreased by -160.00% | -0.23 Decreased by -13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -20.54 M Decreased by -76.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -14.87 M Decreased by -56.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 290.00 K Increased by +N/A% | -16.50 M Decreased by -18.99% | Decreased by -5.69 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -12.96 M Decreased by -28.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.61 M Decreased by -17.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.48 M Decreased by -4.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -13.86 M Decreased by -66.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -10.05 M Decreased by -157.53% | Decreased by N/A% Decreased by N/A% |